Patent: 8,101,185
Summary for Patent: 8,101,185
| Title: | Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation |
| Abstract: | The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. |
| Inventor(s): | Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Motoo Yamasaki, Nobuo Hanai, Emi Hosaka, Kazuya Yamano |
| Assignee: | Kyowa Kirin Co Ltd |
| Application Number: | US12/818,363 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,101,185
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Octapharma Pharmazeutika Produktionsges.m.b.h. | WILATE | von willebrand factor/coagulation factor viii complex (human) | For Injection | 125251 | December 20, 2010 | ⤷ Start Trial | 2030-06-18 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,101,185
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2001294198 | ⤷ Start Trial |
| Australia | 9419801 | ⤷ Start Trial |
| Brazil | 0114475 | ⤷ Start Trial |
| Canada | 2424602 | ⤷ Start Trial |
| Canada | 2785941 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
